- Home
- AKRO vs CVCO Comparison
AKRO vs CVCO Comparison
Compare AKRO & CVCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKRO
- CVCO
- Stock Information
- Founded
- AKRO 2017
- CVCO 1965
- Country
- AKRO United States
- CVCO United States
- Employees
- AKRO N/A
- CVCO N/A
- Industry
- AKRO Biotechnology: Pharmaceutical Preparations
- CVCO Homebuilding
- Sector
- AKRO Health Care
- CVCO Consumer Discretionary
- Exchange
- AKRO Nasdaq
- CVCO Nasdaq
- Market Cap
- AKRO 3.7B
- CVCO 4.3B
- IPO Year
- AKRO 2019
- CVCO N/A
- Fundamental
- Price
- AKRO $54.07
- CVCO $527.12
- Analyst Decision
- AKRO Buy
- CVCO Buy
- Analyst Count
- AKRO 10
- CVCO 2
- Target Price
- AKRO $73.56
- CVCO $522.50
- AVG Volume (30 Days)
- AKRO 4.1M
- CVCO 169.5K
- Earning Date
- AKRO 11-07-2025
- CVCO 10-30-2025
- Dividend Yield
- AKRO N/A
- CVCO N/A
- EPS Growth
- AKRO N/A
- CVCO 37.54
- EPS
- AKRO N/A
- CVCO 24.29
- Revenue
- AKRO N/A
- CVCO $2,143,782,000.00
- Revenue This Year
- AKRO N/A
- CVCO $10.79
- Revenue Next Year
- AKRO N/A
- CVCO $5.69
- P/E Ratio
- AKRO N/A
- CVCO $21.81
- Revenue Growth
- AKRO N/A
- CVCO 15.76
- 52 Week Low
- AKRO $21.34
- CVCO $393.53
- 52 Week High
- AKRO $58.40
- CVCO $602.57
- Technical
- Relative Strength Index (RSI)
- AKRO 68.64
- CVCO 47.35
- Support Level
- AKRO $53.40
- CVCO $491.29
- Resistance Level
- AKRO $54.31
- CVCO $579.36
- Average True Range (ATR)
- AKRO 0.24
- CVCO 28.05
- MACD
- AKRO -0.18
- CVCO -4.92
- Stochastic Oscillator
- AKRO 74.03
- CVCO 35.51
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
About CVCO Cavco Industries Inc. When Issued
Cavco Industries Inc designs and produces factory-built homes under the Cavco Homes, Fleetwood Homes, and Palm Harbor Homes brands. It also produces modular homes, park model homes, and vacation cabins, as well as commercial structures, among others. The company operates principally in two segments: Factory-built housing, which includes wholesale and retail systems-built housing operations, and the Financial services segment, which includes manufactured housing consumer finance and insurance. Cavco receives a majority of its revenue from the Factory-built housing segment.